Blood biomarker may detect lung cancer
Researchers at Cleveland Clinic studied the blood serum of 284 subjects, 48% of whom were female with a mean age of 68 years. …
Researchers at Cleveland Clinic studied the blood serum of 284 subjects, 48% of whom were female with a mean age of 68 years. …
Studies have shown that breast cancer patients treated with radiation therapy have improved local-regional recurrence, and breast cancer-specific survival after breast-conserving surgery and overall survival (OS) after mastectomy. Long-term follow-up of historic radiation therapy trials for breast cancer has demonstrated a potential increase in cardiac mortality. However, these studies used earlier modes of radiation therapy including Cobalt and orthovoltage radiotherapy, and did not employ CT-based planning, which allows for greater cardiac avoidance. Three recent studies suggest that cardiac mortality has not been greater for patients treated for left-sided breast cancer since the 1980s, when techniques allowing for greater cardiac avoidance became more commonplace[1-3]. …
According to the American Cancer Society, more than 18,000 people will be diagnosed with esophageal cancer in the U.S. in 2014 and almost 15,500 people will die from it…
“Our goal is to provide information about trends and patterns to bring to light what’s going on around the world so that funds can be allocated and policy developed as needed,” says Lindsay Boyers, medical student at Georgetown University, working in the lab or Robert Dellavalle, MD, PhD, MSPH investigator at the University of Colorado Cancer Center, associate professor of dermatology at the University of Colorado School of Medicine, and the paper’s senior author. The paper used data from the Global Burden of Disease Study, an ongoing project funded by the Bill and Melinda Gates Foundation to collect a billion data points describing the distribution of the world’s diseases. Of the 269 diseases in the GBD database, this study compares rates in developed versus developing countries of Ebola, malignant melanoma, basal and squamous cell carcinoma, decubitus ulcer, bacterial skin diseases, cellulitis, varicella (including chickenpox, congenital varicella infection, and herpes zoster), syphilis, measles, and dengue. Specifically, findings show that in 2010 the measles death rate was 197 times greater in developing countries than in developed countries, but this ratio was down from 345-to-1 in 1990. …
This switch is driven by p53, the well-documented tumor-suppressing protein. The UNC researchers showed that increasing the level of p53 in scar-forming cells significantly reduced scarring and improved heart function after heart attack. The finding, which was published today in the journal Nature, shows that it is possible to limit the damage wrought by heart attacks, which strike nearly one million people in the United States each year. Heart disease accounts for one in four deaths every year…
University of Iowa researchers have found a gene in a soil-dwelling amoeba that functions similarly to the main tumor-fighting gene found in humans, called PTEN. …
Pancreatic cancer is a stealthy cancer that is usually detected at very late stages and has a 5-year survival rate of less than 5 percent. …
“Unfortunately, chronic pain is a condition that many breast cancer patients endure after mastectomy,” said Mohamed Tiouririne, M.D., lead author and associate professor of anesthesiology at the University of Virginia, Charlottesville. “Our findings indicate that intravenous (I.V.) lidocaine can protect mastectomy patients from developing chronic pain, possibly due to the anti-inflammatory effects associated with the medication.” In the study, 61 women who underwent mastectomy were randomly divided into two groups…
“This drug delivery system is DNA-based, which means it is biocompatible and less toxic to patients than systems that use synthetic materials,” says Dr. Zhen Gu, senior author of a paper on the work and an assistant professor in the joint biomedical engineering program at NC State and UNC Chapel Hill. …
The researchers at Thomas Jefferson University examined colon cancer samples from 281 patients and compared those tissues to nearby colon tissue that wasn’t cancerous. They found that guanylin production — measured by number of messenger RNAs for guanylin contained in each cell — decreased 100 to 1,000 times in more than 85 percent of colon cancers tested. They verified their results by also staining for the guanylin hormone production in slices of the tissue samples. …